These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37436237)

  • 1. Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review.
    Lima LM; Aurilio RB; Fonseca AR; Parente AAAI; Sant'Anna MFBP; Sant'Anna CC
    Rev Paul Pediatr; 2023; 42():e2022084. PubMed ID: 37436237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO).
    Pettipher C; Benitha R
    Ann Rheum Dis; 2020 Feb; 79(2):292-299. PubMed ID: 31791950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.
    Calzada-Hernández J; Anton-López J; Bou-Torrent R; Iglesias-Jiménez E; Ricart-Campos S; Martín de Carpi J; ; Torrente-Segarra V; Sánchez-Manubens J; Giménez-Roca C; Rozas-Quesada L; Juncosa-Morros MT; Fortuny C; Noguera-Julian A
    Pediatr Rheumatol Online J; 2015 Dec; 13():54. PubMed ID: 26635208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM; Chen DY
    Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
    [No Abstract]   [Full Text] [Related]  

  • 6. Screening for acquired latent tuberculosis in rheumatoid arthritis patients on tumor necrosis factor inhibition therapy in Southern California.
    Goel N; Torralba K; Downey C; Salto L
    Clin Rheumatol; 2020 Aug; 39(8):2291-2297. PubMed ID: 32112272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
    Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
    Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
    Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
    Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.
    Souto A; Maneiro JR; Salgado E; Carmona L; Gomez-Reino JJ
    Rheumatology (Oxford); 2014 Oct; 53(10):1872-85. PubMed ID: 24821849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.
    Cantini F; Niccoli L; Capone A; Petrone L; Goletti D
    Expert Opin Drug Saf; 2019 May; 18(5):415-425. PubMed ID: 31066297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
    Kilic O; Kasapcopur O; Camcioglu Y; Cokugras H; Arisoy N; Akcakaya N
    Rheumatol Int; 2012 Sep; 32(9):2675-9. PubMed ID: 21789614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013-2018.
    Jung SM; Han M; Kim EH; Jung I; Park YB
    Arthritis Res Ther; 2022 Jun; 24(1):157. PubMed ID: 35761359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
    Medina-Gil C; Dehesa L; Vega A; Kerdel F
    Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active tuberculosis infection in moroccan patients with rheumatic diseases under biologic therapy: A multicenter national study.
    Aachari I; Tahiri L; Elolemy G; Taik FZ; Afilal S; Fellous S; Berkchi JM; Rkain H; Bahiri R; Majjad A; Achemlal L; Ousehal S; Nassar K; Mkinsi O; Mahha FZ; El Aissaoui A; Chaoui I; Harzy T; Youssoufi T; Hassikou H; Kherrab A; Niamane R; Eddarami J; Ichchou L; Ghozlani I; El Bouchti I; Abourazzak FZ; Razine R; Allali F
    Int J Mycobacteriol; 2022; 11(2):175-182. PubMed ID: 35775550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
    Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
    Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: The importance of Mantoux and Quantiferon-TB Gold tests.
    Malaviya AN; Aggarwal VK; Rawat R; Baghel S; Thakran R; Zaheer Q; Garg S; Kapoor S
    Int J Rheum Dis; 2018 Aug; 21(8):1563-1571. PubMed ID: 29345081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
    Lee CK; Wong SHV; Lui G; Tang W; Tam LS; Ip M; Hung E; Chen M; Wu JC; Ng SC
    J Crohns Colitis; 2018 Jul; 12(8):954-962. PubMed ID: 29757355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latent and active tuberculosis development in patients with rheumatoid arthritis receiving biologic disease-modifying antirheumatic drugs: A single-center prospective study.
    Hai BB; Anh TL; Thi Thu PN; Van HN; Van GV; Van DH
    PLoS One; 2024; 19(1):e0295048. PubMed ID: 38206946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.